Study Evaluating the Pharmacokinetic Profile of RhuDex® in a Tablet Formulation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00704119|
Recruitment Status : Terminated (Following an SAE, study was put on hold. After performing preclinical follow-up studies, volunteers were no longer available for continuation.)
First Posted : June 24, 2008
Last Update Posted : March 24, 2010
RhuDex® (code number AV1142742) is a novel, orally bioavailable, low molecular weight modulator of co-stimulation of T lymphocytes. RhuDex® binds to the protein CD80 (also known as B7-1) on the surface of antigen-presenting cells and inhibits its interaction with CD28 (but not with CTLA-4) presented by CD4+ T lymphocytes.
RhuDex® is being developed for the treatment of rheumatoid arthritis. To improve oral bioavailability, the study drug has to be co-administered with an alkaline buffer that increases gastric pH values. In previous in vitro and phase I studies, meglumine has been identified as the most effective buffer. Study CT 5002 is designed to evaluate the bioavailability of four increasing doses of RhuDex®, combined with a fixed amount of meglumine using a tablet formulation, under fed and fasted conditions as well as with co-administration of the proton pump inhibitor pantoprazole. Furthermore, dose/plasma concentration proportionality for single dosing and accumulation effects for repeat dosing of RhuDex® will be evaluated.
|Condition or disease||Intervention/treatment||Phase|
|Pharmacokinetics||Drug: RhuDex®||Phase 1|
This is an open-label, non-randomized, monocentric Phase I study to evaluate the pharmacokinetic profile of single-dosed and repeat-dosed RhuDex® using a tablet formulation as well as to assess the effect of food and the effect with co-administration of a proton pump inhibitor on the bioavailability of RhuDex®.
12 healthy male subjects will receive study medication in 8 different treatment periods in 4 subsequent steps A, B, C and D.
Within steps A and B, the subjects will receive different treatments (4 in A and 2 in B), sequentially. There will be a wash-out period of at least 4 days between each of the 8 different treatments/treatment periods of steps A, B, C and D.
In Step A, each subject will receive increasing doses of RhuDex® in 4 subsequent treatments. In Step B, each subject will receive 2 different doses of RhuDex® preceded by pantoprazole intake, in 2 subsequent treatments, and in Step C the RhuDex® dosing will be preceded by a standardized high-fat, high-calorie meal. In Step D, RhuDex® will be administered twice daily for 7 days.
For assessing the pharmacokinetic profile of RhuDex® in steps A, B and C, blood samples will be collected prior to and at different intervals after RhuDex® administration. In step D, blood samples will be collected on Days 1, 2, 4 and 7. Cmin, Cmax, tmax, t½ term, CL/F, AUC(0-t), and AUC(0-∞) of RhuDex® will be analyzed.
Safety will be evaluated by regular observation and documentation of AEs, vital signs, physical examination, ECG, and laboratory parameters.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||CT 5002 An Open-label, Non-randomized, Monocentric Phase I Study Evaluating the Pharmacokinetic Profile of RhuDex® Using a Tablet Formulation|
|Study Start Date :||May 2008|
|Actual Primary Completion Date :||July 2008|
|Actual Study Completion Date :||August 2008|
- Drug: RhuDex®
Other Name: AV1142742
- Treatment A.1: 31.65 mg RhuDex® once N=12
- Treatment A.2: 63.33 mg RhuDex® once N=12
- Treatment A.3: 126.63 mg RhuDex® once N=12
- Treatment A.4: 253.26 mg RhuDex® once N=12
- Treatment B.1: 31.65 mg RhuDex® once N=12
- Treatment B.2: selected dose of RhuDex® once N=12
- Treatment C: selected dose of RhuDex® once N=12
- Treatment D: selected dose of RhuDex® twice daily for 6 days N=12
- To assess the relationship between the dose of RhuDex® administered and the plasma concentrations achieved following single and repeated doses under fed and/or fasted conditions and with/without administration of pantoprazole [ Time Frame: 24 -96h pharmakokinetic laboratory values ]
- To gain further safety and tolerability data of RhuDex® [ Time Frame: during treatment phase and 28 days afterwards ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00704119
|Charles River Clinical Services Edinburgh Ltd|
|Edinburgh, Scotland, United Kingdom, EH14 4AP|
|Principal Investigator:||Stuart Mair, MBChB, DROCG,DCPSA||Syneos Health|